Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 110 publications.
Skip to main content
Wilson MR, Castaman G, Thomas W, Millar CM, Escolar G, Miesbach WA, McDade CL, Tomic R, Yan S. Cost-effectiveness of voncento prophylaxis versus on-demand treatment in von willebrand disease in the United Kingdom. Blood Adv. 2025 Mar 25;9(6):1312-9. doi: 10.1182/bloodadvances.2024014376
Megias-Vericat JE, Escolar G, Wilson MR, Mendez P, McDade CL, Barrientos LV, Tomic R, Panebianco M, Linden S, Yan S. Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain. J Med Econ. 2025 Mar 7;28(1):436-45. doi: 10.1080/13696998.2025.2474886
Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs. Expert Rev Vaccines. 2024 Dec 31;23(1):879-86. doi: 10.1080/14760584.2024.2409662
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. J Med Econ. 2024 Dec;27(1):758-65. doi: 10.1080/13696998.2024.2351762
Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States. J Manag Care Spec Pharm. 2024 Aug;30(8):805-16. doi: 10.18553/jmcp.2024.23214
Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Real-world impact of pneumococcal conjugate vaccines on invasive pneumococcal disease for serotypes missing prespecified efficacy threshold in immunogenicity trials. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Golan Y, Amin AN, Wilson M, Nguyen D, Kvasz M. Clinical and economic outcomes of microbiome therapy for preventing recurrence in recurrent clostridioides difficile infection (Cdi) in the us: comparison of fecal microbiota spores, live-brpk (formerly Ser-109) Vs fecal microbiota, live-Jslm. Poster presented at the Digestive Disease Week (DDW) 2024; May 18, 2024. Washington, DC.
Golan Y, Amin A, Dubberke E, Wilson M, Nguyen D, Kvasz M. Budget impact analysis of VOWST™ oral spores (VOS, formerly SER-109) for prevention of recurrent clostridioides difficile infection (CDI) in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-2):S8.
Curtis R, Decker-Palmer M, Wilson MR, McDade CL, Lin CW, Wallick C, Ko RH. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Poster presented at the 65th ASH Annual Meeting & Exposition 2023; December 11, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Supplement 1):5053-4. doi: 10.1182/blood-2023-181062
Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Long-term impact of the gene therapy etranacogene dezaparvovec for the treatment of hemophilia B in the United States. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S36-7.
Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of five pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12(7):1809-21. doi: 10.1007/s40121-023-00828-8
Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, Ellsbury GF, Perdrizet J. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023 Jun 28;11(7):1168. doi: 10.3390/vaccines11071168
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Lopez A, del Amo M, Perdizet J, McDade C, Wilson M. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine pediatric national immunization program in Spain. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S99. doi: 10.1016/j.jval.2022.09.482
Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P. Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S95. doi: 10.1016/j.jval.2022.09.464
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Sundaram V, Wasserman M, Palmborg A, McDade C, Dorange AC, Wilson M, Perdrizet J. Comparing the public health impact of the pediatric 15- and 20-valent pneumococcal conjugate vaccine in Sweden. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.
Sundaram V, Perdrizet J, Wasserman M, Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A. Comparing the public health impact of switching to pediatric 13-valent pneumococcal conjugate vaccine in the near-term and higher-valent pneumococcal conjugate vaccines in the long-term in the Netherlands. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.
Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece. Previously presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.
Teixeira R, da Silva Maia AS, Sundaram V, Wasserman M, Horn EK, McDade C, Wilson M, Perdizet J. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine paediatric national immunisation programme in Portugal. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9
Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Lucas A, Wilson M, Sings HL, Pugh S, Jones D, Farkouh R, Gessner B, Wasserman M. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. International journal of infectious diseases and therapy. 2019 Dec;4(4):56-66. doi: 10.11648/j.ijidt.20190404.12
Wilson M, Moffatt M, Mignon A, McDade C, Wasserman M. Potential public health impact model assessing the switch back to use of the 13-valent infant pneumococcal conjugate vaccine in Belgium on children under 18 years. Poster presented at the World Society for Pediatric Infectious Diseases (WSPID) Conference; November 2019. Manila, Philippines.
Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 Oct;35(10):1761-7. doi: 10.1080/03007995.2019.1623185
Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA. Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: leveraging real-world experience from Belgium. Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1
Wasserman M, Palacios MG, Grajales AG, Berenice Baez-Revueltas F, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560-9. doi: 10.1080/21645515.2018.1516491
Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.
Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.
Breton MC, Peloquin F, Wasserman M, Wilson M, McDade C, Farkouh R. Pneumococcal vaccination provides substantial value for money for Canadians. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada. Previously presented at the IDWeek 2017 Conference.
Wilson M, Lucas A. Cost-effectiveness of Vedolizumab compared with Ustekinumab for the treatment of moderately-to-severely active Crohn's Disease in the United Kingdom. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.
Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R. In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Breton MC, Farkouh R, Vojicic J, Wilson M, McDade C, Wasserman M. Modeling reductions in antibiotic prescriptions due to otitis media in Canada as a result of pneumococcal vonjugate vaccination. Poster presented at the IDWeek 2018 Conference; October 5, 2018. San Francisco, CA.
Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X
Walter R, Mamolo C, Welch V, Brockbank J, Cawson M, Knight C, Wilson M. Budget-impact analysis for gemtuzumab ozogamicin in CD33+ acute Myeloid Leukemia. Poster presented at the XXXVII World Congress International Society of Hematology (ISH); September 14, 2018. Vancouver, Canada.
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1